Sugi Predict

Sugi Predict / Compounds / SCHEMBL6319189

SCHEMBL6319189

SCHEMBL6319189

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](COCc1ccccc1)NC

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 4/20 0.42
▸ MMP3 P08254 4/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ MMP9 P14780 3/20 0.42
▸ MAOB P27338 1/20 0.42
▸ MMP14 P50281 1/20 0.42
▸ MMP8 P22894 3/20 0.41
▸ MME P08473 1/20 0.41
▸ FOLH1 Q04609 1/20 0.40
▸ CTSS P25774 3/20 0.40
▸ CTSL P07711 2/20 0.39
▸ CTSB P07858 2/20 0.39
▸ CTSK P43235 1/20 0.39
▸ S1PR1 P21453 2/20 0.39
▸ OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8905274 0.93 MAOB (0.44) MMP1MMP3MMP9MAOBMMP8
SCHEMBL6319028 0.82 ALDH1A1 (0.49) MMP1MMP9MMP14MMP8MME
SCHEMBL6324685 0.82 ALDH1A1 (0.49) MMP1MMP9MMP14MMP8MME
SCHEMBL6317975 0.81 PPARA (0.45) MMP1MMP3PPARAMMP9MAOB
SCHEMBL7894478 0.78 CTRB1 (0.57) CTSSCTSLCTSBCTSKOPRK1
SCHEMBL6320145 0.78 TACR1 (0.39) MMP1MMP3MMP9MAOBMMP8
SCHEMBL8905743 0.78 MAOB (0.42) MMP1MMP3MMP9MAOBMMP8
SCHEMBL4427112 0.77 FCER2 (0.53) MMP9MMP8MMECTSSCTSL
SCHEMBL4426088 0.77 FCER2 (0.53) MMP9MMP8MMECTSSCTSL
SCHEMBL6317992 0.77 FCER2 (0.53) MMP9MMP8MMECTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 MMP1 2132/4885MMP3 1814/4885PPARA 942/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR MMP1 2382/4885MMP3 1737/4885PPARA 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.